Study Objective: Obstructive sleep apnea is prevalent among people with asthma, but underlying mechanisms remain unknown. Inhaled corticosteroids may contribute. We tested the effects of orally inhaled fl uticasone propionate (FP) on upper airway (UAW) during sleep and wakefulness. Study design: 16-week single-arm study. Participants: 18 (14 females, mean [ ± SD] age 26 ± 6 years) corticosteroid-naïve subjects with mild asthma (FEV 1 89 ± 8% predicted). Interventions: High dose (1,760 mcg/day) inhaled FP. Measurements: (1) UAW collapsibility (passive critical closing pressure [Pcrit]); (2) tongue strength (maximum isometric pressure-Pmax, in KPa) and endurance-time (in seconds) able to maintain 50% Pmax across 3 trials (Ttot)-at anterior and posterior locations; (3) fat fraction and volume around UAW, measured by magnetic resonance imaging in three subjects. Results: Pcrit overall improved (became more negative) (mean ± SE) (-8.2 ± 1.1 vs. -12.2 ± 2.2 cm H 2 O, p = 0.04); the response was dependent upon baseline characteristics, with older, male gender, and worse asthma control predicting Pcrit deterioration (less negative). Overall, Pmax increased (anterior p = 0.02; posterior p = 0.002), but Ttot generally subsided (anterior p = 0.0007; posterior p = 0.06), unrelated to Pcrit response. In subjects studied with MRI, fat fraction and volume increased by 20.6% and 15.4%, respectively, without Pcrit changes, while asthma control appeared improved. Conclusions: In this study of young, predominantly female, otherwise healthy subjects with well-controlled asthma and stiff upper airways, 16-week high dose FP treatment elicited Pcrit changes which may be dependent upon baseline characteristics, and determined by synchronous and reciprocally counteracting local and lower airway effects. The long-term implications of these changes on sleep disordered breathing severity remain to be determined.
S C I E N T I F I C I N V E S T I G A T I O N SG rowing evidence suggests that asthma patients have an increased predisposition for obstructive sleep apnea (OSA). Studies consistently fi nd higher prevalence of OSA symptoms among asthma patients.1-5 In a 14-year longitudinal study, asthma emerged as an independent risk factor for incident habitual snoring when adjusting for relevant confounders, including body mass index (BMI) at baseline and its change in time.6 Likewise, the prevalence of OSA diagnosed on polysomnography (PSG) is high (88% to 95.5%) in diffi cult-to-control asthma, 7,8 and follows asthma severity with 58% in moderate asthma versus 12% in controls.
7The mechanisms underlying this increased risk for OSA in asthma remain unknown. Apart from traditional OSA risk factors,
BRIEF SUMMARYCurrent Knowledge/Study Rationale: Obstructive sleep apnea is more prevalent among people with asthma of increasing severity, but underlying mechanisms remain unknown. Inhaled corticosteroids may play a role. Study Impact: Sixteen-week treatment with inhaled fl uticasone elicited individual responses in upper airway collapsibility depe...